{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:21:59Z","timestamp":1790144519519,"version":"4.0.1"},"reference-count":54,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pain is the insignia of sickle cell disease and the acute painful crisis is the number-one cause of hospital admissions. Tissue damage due to vaso-occlusion releases numerous inflammatory mediators that initiate the transmission of painful stimuli and the perception of pain. The acute sickle cell painful crisis evolves along four distinct phases coupled with changes in certain markers of the disease. Hospital readmission within 1 week occurs in about 16% of discharged patients. Failure to treat acute pain aggressively may lead to chronic pain syndrome. Management of sickle pain is primarily pharmacologic in nature, and opioids are the analgesics used most often. Cellular and molecular mechanisms of opioids explain individual differences among patients and justify the use of individualized treatment plans.<\/jats:p>","DOI":"10.1182\/asheducation-2007.1.97","type":"journal-article","created":{"date-parts":[[2007,11,16]],"date-time":"2007-11-16T18:08:40Z","timestamp":1195236520000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":86,"title":["Current Issues in Sickle Cell Pain and Its Management"],"prefix":"10.1182","volume":"2007","author":[{"given":"Samir K.","family":"Ballas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111702354721000_R1","unstructured":"Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease. Basic Principles and Clinical Picture. New York: Raven Press; 1994."},{"key":"2019111702354721000_R2","doi-asserted-by":"crossref","unstructured":"Serjeant GR. Sickle Cell Disease, 3rd ed. New York: Oxford University Press; 2001.","DOI":"10.1046\/j.1365-2141.2001.02557.x"},{"key":"2019111702354721000_R3","unstructured":"Ballas SK. Sickle Cell Pain. Progress in Pain Research and Management. Vol. 11. Seattle, WA: IASP Press; 1998."},{"key":"2019111702354721000_R4","unstructured":"Benjamin LJ, Dampier CD, Jacox A, et al. Guideline for the Management of Acute and Chronic Pain in Sickle Cell Disease. American Pain Society Clinical Practice Guidelines Series No. 1. Glenview, IL; 1999."},{"key":"2019111702354721000_R5","unstructured":"Benjamin LJ. Nature and treatment of the acute painful episode in sickle cell disease. In: Steinberg MH et al, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management. Cambridge; 2001:671\u2013710."},{"key":"2019111702354721000_R6","doi-asserted-by":"crossref","unstructured":"Benjamin LJ, Payne R. Pain in sickle cell disease: a multidimensional construct. In: Pace B, ed. Renaissance of Sickle Cell Disease Research in the Genomic Era. London: Imperical College Press; 2007:99\u2013118.","DOI":"10.1142\/9781860947964_0007"},{"key":"2019111702354721000_R7","doi-asserted-by":"crossref","unstructured":"Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79:17\u201325.","DOI":"10.1002\/ajh.20336"},{"key":"2019111702354721000_R8","doi-asserted-by":"crossref","unstructured":"Boros L, Thomas C, Weiner WJ. Large cerebral vessel disease in sickle cell anemia. J Neurol Neurosurg Psych. 1976;39:1236\u20131239.","DOI":"10.1136\/jnnp.39.12.1236"},{"key":"2019111702354721000_R9","doi-asserted-by":"crossref","unstructured":"Powars D, Wilson B, Imbus C, et al. The natural history of stroke in sickle cell disease. Am J Med. 1978;65:461\u2013471.","DOI":"10.1016\/0002-9343(78)90772-6"},{"key":"2019111702354721000_R10","doi-asserted-by":"crossref","unstructured":"Powars DR. Sickle cell anemia and major organ failure. Hemoglobin. 1990;14:573\u2013598.","DOI":"10.3109\/03630269009046967"},{"key":"2019111702354721000_R11","doi-asserted-by":"crossref","unstructured":"Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle cell disease pathophysiology. Blood. 1991;77:214\u2013237.","DOI":"10.1182\/blood.V77.2.214.214"},{"key":"2019111702354721000_R12","doi-asserted-by":"crossref","unstructured":"Francis RB, Johnson CS. Vascular occlusion in sickle cell disease: current concepts and unanswered questions. Blood. 1991;77:1405\u20131404.","DOI":"10.1182\/blood.V77.7.1405.1405"},{"key":"2019111702354721000_R13","doi-asserted-by":"crossref","unstructured":"Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol Oncol Clin N Am. 2005;19:771\u2013781.","DOI":"10.1016\/j.hoc.2005.08.002"},{"key":"2019111702354721000_R14","doi-asserted-by":"crossref","unstructured":"Ballas SK, Mohandas N. Sickle red cell microrheology and sickle blood rheology. Microcirculation. 2004;11:209\u2013225.","DOI":"10.1080\/10739680490279410"},{"key":"2019111702354721000_R15","doi-asserted-by":"crossref","unstructured":"Kaul DK, Hebbel RP. Hypoxia\/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106:411\u2013420.","DOI":"10.1172\/JCI9225"},{"key":"2019111702354721000_R16","doi-asserted-by":"crossref","unstructured":"Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337\u2013338.","DOI":"10.1172\/JCI10726"},{"key":"2019111702354721000_R17","unstructured":"Fields HL. Pain. New York: McGraw-Hill; 1987."},{"key":"2019111702354721000_R18","unstructured":"Cousins MJ. John J Bonica distinguished lecture. Acute pain and the injury response: immediate and prolonged effects. Reg Anesth. 1989;14:162\u2013179."},{"key":"2019111702354721000_R19","unstructured":"Cousins MJ. Acute post operative pain. In: Wall PD, Melzack R, eds. Textbook of Pain, 3rd ed. New York: Churchill Livingstone; 1994:357\u2013385."},{"key":"2019111702354721000_R20","unstructured":"Katz N, Ferrante FM. Nociception. In: Ferrante FM, VadeBoncoeur TR, eds. Post Operative Pain Management. New York: Churchill Livingstone; 1993:17\u201367."},{"key":"2019111702354721000_R21","unstructured":"McMahon SB, Koltzeninburg M, eds. Wall and Melzack\u2019s Textbook of Pain, 5th ed. Elsevier, Churchill Livingstone; 2006."},{"key":"2019111702354721000_R22","unstructured":"Loeser JD, Butler SH, Chapman CR, Turk DC, eds. Bonica\u2019s Management of Pain, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001."},{"key":"2019111702354721000_R23","doi-asserted-by":"crossref","unstructured":"Dunn MJ, Hood VL. Prostaglandins and the kidney. Am J Physiol. 1977;233:F169\u2013F184.","DOI":"10.1152\/ajprenal.1977.233.3.F169"},{"key":"2019111702354721000_R24","unstructured":"Ballas SK, Reyes PE. Peripheral neuropathy in adults with sickle cell disease. Am J Pain Med. 1997;71:53\u201358."},{"key":"2019111702354721000_R25","doi-asserted-by":"crossref","unstructured":"Ballas SK, Smith ED. Red blood cell changes during the evolution of the sickle cell painful crisis. Blood. 1992;79:2154\u20132163.","DOI":"10.1182\/blood.V79.8.2154.2154"},{"key":"2019111702354721000_R26","doi-asserted-by":"crossref","unstructured":"Akinola NO, Stevens SME, Franklin IM, et al. Rheological changes in the prodromal and established phases of sickle cell vaso-occlusive crisis. Br J Haematol. 1992;81:598\u2013602.","DOI":"10.1111\/j.1365-2141.1992.tb02998.x"},{"key":"2019111702354721000_R27","doi-asserted-by":"crossref","unstructured":"Ballas SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin. 1995;19:323\u2013333.","DOI":"10.3109\/03630269509005824"},{"key":"2019111702354721000_R28","doi-asserted-by":"crossref","unstructured":"Beyer J, Simmons L, Woods GM, Woods PM. A chronology of pain\/comfort in children with sickle cell disease. Arch Ped Adolescent Med. 1999;153:913\u2013920.","DOI":"10.1001\/archpedi.153.9.913"},{"key":"2019111702354721000_R29","doi-asserted-by":"crossref","unstructured":"Jacob E, Beyer JE, Miaskowski C, Savedra M, Treadwell M, Styles L. Are there phases to the vaso-occlusive painful episode in sickle cell disease? J Pain Symptom Manage. 2005;29:392\u2013400.","DOI":"10.1016\/j.jpainsymman.2004.07.006"},{"key":"2019111702354721000_R30","doi-asserted-by":"crossref","unstructured":"Jacob E, Miaskowski C, Savedra M, Beyer JE, Treadwell M, Styles L. Changes in intensity, location, and quality of vaso-occlusive pain in children with sickle cell disease. Pain. 2003;102:187\u2013193.","DOI":"10.1016\/s0304-3959(02)00374-3"},{"key":"2019111702354721000_R31","doi-asserted-by":"crossref","unstructured":"Cordeiro NJ, Oniyangi O. Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database Syst Rev. 2004;3:CD004448.","DOI":"10.1002\/14651858.CD004448.pub2"},{"key":"2019111702354721000_R32","doi-asserted-by":"crossref","unstructured":"Brousseau DC, Scott JP, Hillery CA, Panepinto JA. The effect of magnesium on length of stay for pediatric sickle cell pain crisis. Acad Emerg Med. 2004;11:968\u2013972.","DOI":"10.1197\/j.aem.2004.04.009"},{"key":"2019111702354721000_R33","unstructured":"Ballas SK, Barton F, Castro O, Bellevue R. Narcotic analgesic use among adult patients with sickle cell anemia [abstract]. Blood. 1995;86:642a."},{"key":"2019111702354721000_R34","doi-asserted-by":"crossref","unstructured":"Tobin DL, Holroyd KA, Reynolds RV, Wigal JK. The hierarchical factor structure of the Coping Strategies Inventory. Cognitive Ther Res. 1989;13:343\u2013361.","DOI":"10.1007\/BF01173478"},{"key":"2019111702354721000_R35","doi-asserted-by":"crossref","unstructured":"Nadvi S, Sarnaik S, Ravindranath Y. Low frequency of meperidine associated seizures in sickle cell disease. Clin Pediatr(Phila). 1999;38:459\u2013462;","DOI":"10.1177\/000992289903800803"},{"key":"2019111702354721000_R36","unstructured":"Zsebik G, O\u2019Riordan MA, Berman B, Villela A. Low risk of meperidine-induced seizures in children with sickle cell disease [abstract]. Pediatric Blood Cancer. 2007;48:612."},{"key":"2019111702354721000_R37","doi-asserted-by":"crossref","unstructured":"Chulamokha L, Scholand SJ, Riggio JM, Ballas SK, Horn D, DeSimone JA. Bloodstream infections in hospitalized adults with sickle cell disease: a retrospective analysis. Am J Hematol. 2006;81:723\u2013728.","DOI":"10.1002\/ajh.20692"},{"key":"2019111702354721000_R38","unstructured":"Graham AW, Schultz TK, Mayo-Smith MF, Ries RK. Principles of Addiction Medicine. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine; 2003."},{"key":"2019111702354721000_R39","doi-asserted-by":"crossref","unstructured":"Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiologica Scand. 2005;49:902\u2013908.","DOI":"10.1111\/j.1399-6576.2005.00772.x"},{"key":"2019111702354721000_R40","doi-asserted-by":"crossref","unstructured":"Uhl GR, Sora I, Wang Z. The m opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci U S A. 1999:96:7752\u20137755.","DOI":"10.1073\/pnas.96.14.7752"},{"key":"2019111702354721000_R41","doi-asserted-by":"crossref","unstructured":"Compton P, Geschwind DH, Alarcon M. Association between human \u03bc-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. Am J Med Gen Part B. 2003;121B:76\u201382.","DOI":"10.1002\/ajmg.b.20057"},{"key":"2019111702354721000_R42","doi-asserted-by":"crossref","unstructured":"Klepstad P, Rakvag TT, Kaasa S, et al. The 118 A \u2192 G polymorphism in the human m-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48:1232\u20131239.","DOI":"10.1111\/j.1399-6576.2004.00517.x"},{"key":"2019111702354721000_R43","unstructured":"Mehta S, Kutlar F, Bailey L, et al. Mu opioid receptor 1 (MOR 1) polymorphisms among patients with sickle cell disease. Oral Presentation. 27th Annual Meeting of the National Sickle Cell Disease Program. Los Angeles, CA; April 18\u201321, 2004."},{"key":"2019111702354721000_R44","doi-asserted-by":"crossref","unstructured":"Kopecky EA, Jacobson S, Joshi P, Konen G. Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Therapeutics. 2004;75:140\u2013146.","DOI":"10.1016\/j.clpt.2003.10.007"},{"key":"2019111702354721000_R45","doi-asserted-by":"crossref","unstructured":"Buchanan ID, Woodward M, Reed GW. Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome. Pediatr Blood Cancer. 2005;45:716\u2013724.","DOI":"10.1002\/pbc.20403"},{"key":"2019111702354721000_R46","doi-asserted-by":"crossref","unstructured":"Weber ML, Hebbel RP, Gupta K. Morphine induces kidney injury in transgenic sickle cellmice [abstract]. Blood. 2005;106:884a\u2013885a.","DOI":"10.1182\/blood.V106.11.3167.3167"},{"key":"2019111702354721000_R47","doi-asserted-by":"crossref","unstructured":"Gupta K, Chen C, Lutty GA, Hebbel RP. Morphine exaggerates retinopathy in transgenic sickle mice [abstract]. Blood. 2005;106:64a\u201365a.","DOI":"10.1182\/blood.V106.11.209.209"},{"key":"2019111702354721000_R48","doi-asserted-by":"crossref","unstructured":"Crain SM, Shen KF. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance\/dependence during chronic cotreatment. Proc Natl Acad Sci U S A. 1995;92:10540\u201310544.","DOI":"10.1073\/pnas.92.23.10540"},{"key":"2019111702354721000_R49","doi-asserted-by":"crossref","unstructured":"Winkelmuller M, Winkelmuller W. Long-term effects of continuous intrathecal opioids treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996; 85:458\u2013476.","DOI":"10.3171\/jns.1996.85.3.0458"},{"key":"2019111702354721000_R50","unstructured":"Weissman DE, Haddox JD. Opioid pseudoaddiction: an iatrogenic syndrome. Pain. 1989;26:363\u2013366."},{"key":"2019111702354721000_R51","doi-asserted-by":"crossref","unstructured":"Mercante S, Ferraera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage. 2003;26:769\u2013775.","DOI":"10.1016\/S0885-3924(03)00258-6"},{"key":"2019111702354721000_R52","doi-asserted-by":"crossref","unstructured":"Katz JL, Higgins ST. The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology. 2003;168:21\u201330.","DOI":"10.1007\/s00213-003-1441-y"},{"key":"2019111702354721000_R53","doi-asserted-by":"crossref","unstructured":"Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs. 2005;19:873\u2013896.","DOI":"10.2165\/00023210-200519100-00005"},{"key":"2019111702354721000_R54","doi-asserted-by":"crossref","unstructured":"Boyer EW, Shannon M. The serotonin syndrome. N Eng J Med. 2005;352:1112\u20131120.","DOI":"10.1056\/NEJMra041867"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/97\/646129\/097_105ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2007\/1\/97\/646129\/097_105ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T06:58:41Z","timestamp":1588057121000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2007\/1\/97\/19153\/Current-Issues-in-Sickle-Cell-Pain-and-Its"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2007.1.97","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}